Entrada Therapeutics, Inc. (TRDA) Profit Margins
Over the twelve months to 2026-06-30, Entrada Therapeutics, Inc. (TRDA) had operating margin -3767.1%, net margin -3537.7%, free cash flow margin -2867.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRDAEntrada Therapeutics, Inc.Follow TRDA — free
—
Price chart with a free account
- Market cap
- 171.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating margin | -2.5% | 22.3% | -621.1% | -3767.1% | |
| Net margin | -5.2% | 31.1% | -565.5% | -3537.7% | |
| FCF margin | 104.0% | -21.2% | -509.6% | -2867.1% |
USD millions · SEC XBRL
Entrada Therapeutics, Inc. — questions
- What is Entrada Therapeutics, Inc.'s operating margin?
- -3767.1% over the twelve months to 2026-06-30.
- What is Entrada Therapeutics, Inc.'s net profit margin?
- -3537.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Entrada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.